VYTRUS BIOTECH, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.38 EUR | +0.85% |
|
+0.85% | +27.96% |
| Apr. 03 | Vytrus Biotech, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Vytrus Biotech, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2024 |
|---|---|---|
| Capitalization 1 | 23.49 | 16.03 |
| Enterprise Value (EV) 1 | 23.75 | 17.06 |
| P/E ratio | - | 21.6 x |
| Yield | - | - |
| Capitalization / Revenue | 6.38 x | 3.5 x |
| EV / Revenue | 6.45 x | 3.73 x |
| EV / EBITDA | 17.8 x | 10.9 x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | 2.79 x |
| Nbr of stocks (in thousands) | 6,910 | 6,735 |
| Reference price 2 | 3.400 | 2.380 |
| Announcement Date | 3/28/23 | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2024 |
|---|---|---|---|
| Net sales 1 | 2.804 | 3.682 | 4.577 |
| EBITDA 1 | 1.006 | 1.337 | 1.571 |
| EBIT 1 | 0.4296 | 0.6447 | 0.7904 |
| Operating Margin | 15.32% | 17.51% | 17.27% |
| Earnings before Tax (EBT) 1 | 0.3092 | 0.4528 | 0.6046 |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS 2 | 0.0600 | - | 0.1101 |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share 2 | - | - | - |
| Announcement Date | 4/25/22 | 3/28/23 | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2024 |
|---|---|---|---|
| Net Debt 1 | 0.6 | 0.26 | 1.03 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | 0.599 x | 0.1946 x | 0.6576 x |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | 11.5% | 13.4% | 13.8% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets | - | - | - |
| Book Value Per Share 2 | 0.6100 | - | 0.8500 |
| Cash Flow per Share 2 | 0.0300 | - | 0.1900 |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | 4/25/22 | 3/28/23 | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.38
EUR
Average target price
3.28
EUR
Spread / Average Target
+37.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +27.96% | 17.2M | |
| +25.94% | 73.51M | |
| -24.59% | 64.56M |
- Stock Market
- Equities
- VYT Stock
- Financials Vytrus Biotech, S.A.
